HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy.
The global HER2 Antibody market is projected to reach US$ 23040 million in 2029, increasing from US$ 13980 million in 2022, with the CAGR of 7.3% during the period of 2023 to 2029.
Monoclonal antibodies targeting HER2 (human epidermal growth factor receptor 2) are used in the treatment of HER2-positive breast cancer. Market trends include the development of next-generation HER2-targeted therapies and combination therapies to enhance treatment efficacy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global HER2 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Genentech Inc
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
Segment by Type
Trastuzumab
Lapatinib
Ado-trastuzumab Emtansine
Pertuzumab
Everolimus
Segment by Application
Hospital
Medical Center
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The HER2 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER2 Antibody Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Trastuzumab
1.2.3 Lapatinib
1.2.4 Ado-trastuzumab Emtansine
1.2.5 Pertuzumab
1.2.6 Everolimus
1.3 Market by Application
1.3.1 Global HER2 Antibody Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Medical Center
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global HER2 Antibody Market Perspective (2018-2029)
2.2 HER2 Antibody Growth Trends by Region
2.2.1 Global HER2 Antibody Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 HER2 Antibody Historic Market Size by Region (2018-2023)
2.2.3 HER2 Antibody Forecasted Market Size by Region (2024-2029)
2.3 HER2 Antibody Market Dynamics
2.3.1 HER2 Antibody Industry Trends
2.3.2 HER2 Antibody Market Drivers
2.3.3 HER2 Antibody Market Challenges
2.3.4 HER2 Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HER2 Antibody Players by Revenue
3.1.1 Global Top HER2 Antibody Players by Revenue (2018-2023)
3.1.2 Global HER2 Antibody Revenue Market Share by Players (2018-2023)
3.2 Global HER2 Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HER2 Antibody Revenue
3.4 Global HER2 Antibody Market Concentration Ratio
3.4.1 Global HER2 Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER2 Antibody Revenue in 2022
3.5 HER2 Antibody Key Players Head office and Area Served
3.6 Key Players HER2 Antibody Product Solution and Service
3.7 Date of Enter into HER2 Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HER2 Antibody Breakdown Data by Type
4.1 Global HER2 Antibody Historic Market Size by Type (2018-2023)
4.2 Global HER2 Antibody Forecasted Market Size by Type (2024-2029)
5 HER2 Antibody Breakdown Data by Application
5.1 Global HER2 Antibody Historic Market Size by Application (2018-2023)
5.2 Global HER2 Antibody Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America HER2 Antibody Market Size (2018-2029)
6.2 North America HER2 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America HER2 Antibody Market Size by Country (2018-2023)
6.4 North America HER2 Antibody Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HER2 Antibody Market Size (2018-2029)
7.2 Europe HER2 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe HER2 Antibody Market Size by Country (2018-2023)
7.4 Europe HER2 Antibody Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HER2 Antibody Market Size (2018-2029)
8.2 Asia-Pacific HER2 Antibody Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific HER2 Antibody Market Size by Region (2018-2023)
8.4 Asia-Pacific HER2 Antibody Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HER2 Antibody Market Size (2018-2029)
9.2 Latin America HER2 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America HER2 Antibody Market Size by Country (2018-2023)
9.4 Latin America HER2 Antibody Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HER2 Antibody Market Size (2018-2029)
10.2 Middle East & Africa HER2 Antibody Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa HER2 Antibody Market Size by Country (2018-2023)
10.4 Middle East & Africa HER2 Antibody Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genentech Inc
11.1.1 Genentech Inc Company Detail
11.1.2 Genentech Inc Business Overview
11.1.3 Genentech Inc HER2 Antibody Introduction
11.1.4 Genentech Inc Revenue in HER2 Antibody Business (2018-2023)
11.1.5 Genentech Inc Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG HER2 Antibody Introduction
11.2.4 Novartis AG Revenue in HER2 Antibody Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer HER2 Antibody Introduction
11.3.4 Pfizer Revenue in HER2 Antibody Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Abnova Corporation
11.4.1 Abnova Corporation Company Detail
11.4.2 Abnova Corporation Business Overview
11.4.3 Abnova Corporation HER2 Antibody Introduction
11.4.4 Abnova Corporation Revenue in HER2 Antibody Business (2018-2023)
11.4.5 Abnova Corporation Recent Development
11.5 InvivoGen
11.5.1 InvivoGen Company Detail
11.5.2 InvivoGen Business Overview
11.5.3 InvivoGen HER2 Antibody Introduction
11.5.4 InvivoGen Revenue in HER2 Antibody Business (2018-2023)
11.5.5 InvivoGen Recent Development
11.6 Celltrion
11.6.1 Celltrion Company Detail
11.6.2 Celltrion Business Overview
11.6.3 Celltrion HER2 Antibody Introduction
11.6.4 Celltrion Revenue in HER2 Antibody Business (2018-2023)
11.6.5 Celltrion Recent Development
11.7 Biocon Limited
11.7.1 Biocon Limited Company Detail
11.7.2 Biocon Limited Business Overview
11.7.3 Biocon Limited HER2 Antibody Introduction
11.7.4 Biocon Limited Revenue in HER2 Antibody Business (2018-2023)
11.7.5 Biocon Limited Recent Development
11.8 Bio-Techne
11.8.1 Bio-Techne Company Detail
11.8.2 Bio-Techne Business Overview
11.8.3 Bio-Techne HER2 Antibody Introduction
11.8.4 Bio-Techne Revenue in HER2 Antibody Business (2018-2023)
11.8.5 Bio-Techne Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Genentech Inc
Novartis AG
Pfizer
Abnova Corporation
InvivoGen
Celltrion
Biocon Limited
Bio-Techne
*If Applicable.